Latest Breaking News On - அலெக்ஸ் ஷா - Page 3 : comparemela.com

Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ( EMA ) has validated and accepted its marketing authorization application ( MAA ) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors ( NETs ). The EMA s validation confirms that the submission is sufficiently complete and that it is ready to commence the formal review process.

Hong kongUnited kingdomMark leeZhou yiAtholl tweedie freddy crossleyMarek kaniaBen atwell alex shawPanmure gordonAnnie chengStock exchange of hong kongInternational corporationDrug administrationSurufatinib developmentExchange commissionChina limitedEuropean union